Report Sellers has added a new market research report “Insomnia – Global Market Outlook (2017-23)” to its offerings.
According to Report, Working in rational shifts & stressful work conditions, recent technological advancements and increasing demand for OTC sleep aids are some of the factors favoring the market growth. In addition, presence of large undiagnosed insomnia population pool and untapped markets in developing economies are the key opportunities for the market growth. On the contrary, side effects of benzodiazepine and non-benzodiazepine drugs, expiration of patients and increase in non pharmacological therapies are hindering the market growth.
Insomnia is a sleep disorder where in the person faces difficultly to sleep or remain asleep. The indications include depression, irritability, low stamina and daytime sleepiness. It is a highly predominant disorder that affects millions of people, globally. Insomnia-related conditions are caused due to disruption in circadian rhythm, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions. Furthermore, usage of drugs, such as alcohol, nicotine and caffeine will lead to insomnia.
In 2016, North America accounted for the highest market share in the insomnia market and is expected to maintain its dominance throughout the forecast period. In the U.S., the OTC treatment market is expected to hold a greater CAGR to address its growth in the insomnia pharmacological treatment. It is predicted to earn backing from the increasing utilization of melatonin valerian and roots, outstanding to their crucial advantages such as reduced stress levels and low side effects. Asia Pacific also appeared as a proper opportunity to capitalize on with the lifting disposable income and upsurge in the occurrence of chronic diseases.
Some of the key players in global insomnia market include Astellas, Biocodex S A, Consumer Healthcare Inc., Dainippon Sumitomo, ECR Pharmaceuticals, Eisai Co., Flynn Pharma, Johnson & Johnson, Meda Consumer Healthcare Inc., Merck & Co. Inc., Neurim, Pernix, Therapeutics, Pfizer Inc, Purdue Pharma L.P., Sanofi Pasteur, SkyePharma and Takeda Pharmaceutical Company.
Browse through the complete description and in-depth TOC on “Global Insomnia Market”
What does the Report Offers
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
Global Insomnia Market has been segmented by therapy type covered and regions covered.
Therapy Type Covered:
Disorder Durations Covered:
Disorder Conditions Covered:
Sleep onset and/or Maintenance
Poor Quality of Sleep
Other Disorder Condition
Formulation Types Covered:
Rest of Europe
Rest of Asia Pacific
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
We have a large number of reports in Healthcare Industry which can be accessed in the following link: https://www.reportsellers.com/category/healthcare-market-research-report
About Report Sellers
Report Sellers is a premium market research service provider offering market reports in varied sectors. We have a team of experienced analysts and publishers who continuously track the latest trends in different industries. Report Sellers is a brand of global repute and offers the best suited research services to its clients globally in the most satisfying manner. We have a strong network of industry experts who have successfully delivered complex research assignments in niche and top markets.
For more information, contact